Biosite Reports on Presentation of Preliminary Data From Sepsis Program

    SAN DIEGO and BRUSSELS, Belgium, March 28 /CNW/ -- Biosite Incorporated
(Nasdaq:   BSTE) today announced preliminary results of a sample collection
study aimed at identifying a biomarker panel that could potentially aid in the
assessment for risk of sepsis progression. Sepsis is an often fatal condition
with limited therapeutic options. Clinical investigator, Emanuel P. Rivers,
M.D., MPH, vice chairman and director of research at the department of
emergency medicine at Henry Ford Hospital in Detroit, presented the data at
the 27th International Symposium on Intensive Care and Emergency Medicine
(ISICEM) in Brussels.
    "In this study, we identified a combination of three biomarkers that
performed better when compared to several other individual biomarkers," said
Dr. Rivers. "This preliminary study suggests that these biomarkers may be a
clinically useful tool in the assessment of risk of sepsis progression within
72 hours of patients presenting to the emergency department and meeting the
diagnostic criteria for sepsis.  We look forward to future studies that will
be aimed at substantiating these findings."
    "We are encouraged by this study and will advance this sepsis biomarker
panel to the next step in our clinical process," said Ken Buechler, Ph.D.,
Biosite president and chief scientific officer. "We are on track to launch a
prospective multi-center clinical study in the second quarter of 2007 to
validate the clinical utility of this panel and compile data needed for an FDA
    The biomarkers on the panel, neutrophil gelatinase-associated lipocalin
(NGAL), c-reactive protein (CRP), and macrophage inflammatory protein-3
(MIP-3), were selected from 150 biomarkers studied through the Biosite
Discovery program. The panel incorporates Biosite's proprietary MultiMarker
Index(TM) (MMX) Value feature that uses an algorithm to generate a single
quantitative result from multiple simultaneous biomarker measurements. Biosite
intends to commercialize the panel of biomarkers under the product name
Triage(R) Sepsis Panel.
    In this study, blood samples were collected from approximately 1,000
patients presenting to the emergency department with signs and symptoms of
sepsis.  Samples were analyzed at Biosite using a prototype device.  Following
are preliminary study findings:

    (*)  The study data were based on samples from initial blood draws,
       suggesting that the test may be useful in the rapid assessment of
    (*)  The sepsis biomarker panel may have clinical utility in risk assessment
       of patients presenting to the hospital and meeting diagnostic criteria
       for sepsis.
    (*)  The sepsis biomarker panel performed better as a risk assessment tool
       than markers in the literature, including procalcitonin and C-reactive

    A webcast of Dr. Rivers' presentation will be archived on the Biosite
website at until April 26, 2007. Dr. Rivers is a consultant to

    About the Triage Sepsis Panel
    The Triage Sepsis Panel is a rapid point-of-care test intended to use
simultaneous measurements of MIP-3, CRP and NGAL to aid in the assessment for
risk of sepsis progression within 72 hours of patients presenting to the
emergency department and meeting diagnostic criteria for sepsis.  Biosite
expects to commence a multi-center validation study called MINDSET
(MultiMarker Index for the Risk Assessment of Sepsis in the Emergency
Department) in the second quarter of 2007.  The study is aimed at generating
data to support a submission to the U.S. Food and Drug Administration (FDA).
The Company also plans to seek CE marking for the product later this year.
    Biosite is also evaluating other potential products in the category of
sepsis, including biomarker targets that may be useful in the diagnosis of
septic patients. Biosite has collected approximately 4,000 patient samples
that are useful for the study of sepsis.

    About Biosite Incorporated
    Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis.  The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis and risk assessment of critical diseases and
health conditions. The Biosite(R) Triage(R) rapid diagnostic tests are used in
more than 70 percent of U.S. hospitals and in more than 60 international
markets. Information on Biosite can be found at

    Except for the historical information presented herein, matters discussed
in this press release are forward-looking statements that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed or
implied by such statements. Statements that are not historical facts,
including but not limited to statements that are preceded by, followed by, or
that include the words "will"; "believes"; "should"; "intends"; "anticipates";
"plans"; "expects"; "estimates"; or similar statements are forward-looking
statements. Forward looking statements include statements concerning the
Company's plan to initiate MINDSET, a multi-center study to validate the
clinical utility of the Triage Sepsis Panel, in the second quarter of 2007,
the expectation that the results of the MINDSET study will adequately support
a submission to the FDA for the Triage Sepsis Panel, the Company's plans to
seek CE marking of the Triage Sepsis Panel later this year, the market need
for a rapid sepsis test, the potential utility of a sepsis test,  the
Company's ability to achieve regulatory clearance for a sepsis test and the
Company's ability to develop other potential products in the category of
sepsis. Risks and uncertainties include risks associated with the Company's
ability to initiate and complete the MINDSET study in the timeframe
anticipated, risks that the results of the MINDSET study may not be consistent
with the results from the Company's initial training study, the Company's
ability to manufacture the Triage Sepsis Panel on a commercial scale or other
manufacturing constraints, potential contract disputes or patent conflicts,
the availability of competitive products from companies with greater capital
and resources, the extent to which our products and products under development
are successfully developed and gain market acceptance and other risks in the
clinical, research and development process generally. Other risks that should
be considered include the other risks detailed in Biosite's most recent Annual
Report on Form 10-K, and subsequent SEC filings. The Company disclaims,
however, any intent or obligation to update these forward-looking statements.
Copies of Biosite's public disclosure filings are available from the investor
relations department.

    Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. MultiMarker Index(TM) is a trademark of
Biosite Incorporated. The Company's logo is a trademark of Biosite

For further information:

For further information: Nadine Padilla, Vice President, Corporate & 
Investor Relations, +1-858-805-2820,, or Nicole 
Beckstrand, Manager, Public Relations, +1-619-274-1184,, both of Biosite Incorporated Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890